CVRx touts positive two-year data for heart failure neuromodulation device [Yahoo! Finance]
CVRx, Inc. (CVRX)
Company Research
Source: Yahoo! Finance
The results, published in the Journal of the American College of Cardiology: Heart Failure , demonstrated that patients implanted with the Barostim reported feeling significantly better in a variety of physical and psychosocial measures. Patients received Barostim along with guideline-directed medical therapy and were compared to those who received the latter only. Barostim is a device that mediates baroreflex activation therapy – a type of treatment that uses electrical stimulation on baroreceptors in the carotid sinus. Baroreceptors activate the body's baroreflex, one of the body's homeostatic mechanisms to maintain blood pressure levels. By sending electrical pulses to the baroreceptors, the therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. The Barostim device received US Food and Drug Administration (FDA)-approval for advanced heart failure patients who are not eligible for other devices in 2019, and rec
Show less
Read more
Impact Snapshot
Event Time:
CVRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CVRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CVRX alerts
High impacting CVRx, Inc. news events
Weekly update
A roundup of the hottest topics
CVRX
News
- CVRx to Present at the Piper Sandler 36th Annual Healthcare ConferenceGlobeNewswire
- CVRx, Inc. (NASDAQ: CVRX) had its price target raised by analysts at Craig Hallum from $15.00 to $20.00. They now have a "buy" rating on the stock.MarketBeat
- CVRx Announces Positive Outpatient Payment for Barostim Procedure in 2025GlobeNewswire
- CVRx, Inc. (NASDAQ:CVRX) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year [Yahoo! Finance]Yahoo! Finance
- CVRx, Inc. (NASDAQ: CVRX) had its price target raised by analysts at Lake Street Capital from $12.00 to $15.00. They now have a "buy" rating on the stock.MarketBeat
CVRX
Earnings
- 10/29/24 - Miss
CVRX
Sec Filings
- 11/19/24 - Form 144
- 11/18/24 - Form 144
- 11/7/24 - Form SC
- CVRX's page on the SEC website